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Abstract
Purpose—Different rules for registering multiple primary (MP) cancers are used by cancer 
registries throughout the world, making international data comparisons difficult. This study 
evaluates the effect of Surveillance, Epidemiology, and End Results (SEER) and International 
Association of Cancer Registries (IACR) MP rules on population-based cancer survival estimates.
Methods—Data from five US states and six metropolitan area cancer registries participating in 
the SEER Program were used to estimate age-standardized relative survival (RS%) for first 
cancers-only and all first cancers matching the selection criteria according to SEER and IACR MP 
rules for all cancer sites combined and for the top 25 cancer site groups among men and women.
Results—During 1995–2008, the percentage of MP cancers (all sites, both sexes) increased 25.4 
% by using SEER rules (from 14.6 to 18.4 %) and 20.1 % by using IACR rules (from 13.2 to 15.8 
%). More MP cancers were registered among females than among males, and SEER rules 
registered more MP cancers than IACR rules (15.8 vs. 14.4 % among males; 17.2 vs. 14.5 % 
among females). The top 3 cancer sites with the largest differences were melanoma (5.8 %), 
urinary bladder (3.5 %), and kidney and renal pelvis (2.9 %) among males, and breast (5.9 %), 
melanoma (3.9 %), and urinary bladder (3.4 %) among females. Five-year survival estimates (all 
sites combined) restricted to first primary cancers-only were higher than estimates by using first 
site-specific primaries (SEER or IACR rules), and for 11 of 21 sites among males and 11 of 23 
sites among females. SEER estimates are comparable to IACR estimates for all site-specific 
cancers and marginally higher for all sites combined among females (RS 62.28 vs. 61.96 %).
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Conclusion—Survival after diagnosis has improved for many leading cancers. However, cancer 
patients remain at risk of subsequent cancers. Survival estimates based on first cancers-only 
exclude a large and increasing number of MP cancers. To produce clinically and 
epidemiologically relevant and less biased cancer survival estimates, data on all cancers should be 
included in the analysis. The multiple primary rules (SEER or IACR) used to identify primary 
cancers do not affect survival estimates if all first cancers matching the selection criteria are used 
to produce site-specific survival estimates.
Keywords
Cancer survival; Multiple primary rules; SEER Program
Introduction
Population-based cancer registries serve a vital role by providing useful information for 
directing and monitoring cancer control activities and health policy initiatives [1, 2]. Much 
time and effort has been spent on standardizing the collection, consolidation, analysis, and 
reporting of cancer surveillance data to ensure that the data are high quality, complete, and 
comparable, and therefore suitable to aggregate among cancer registries in the United States 
[3, 4], Canada [5], and within North America [6]. Increasingly, population-based cancer 
registry data are being used to compare cancer incidence and survival rates among countries 
worldwide [7–10].
In the mid-1970s, the Surveillance, Epidemiology, and End Results (SEER) Program [11] 
developed coding rules that helped differentiate a new primary cancer from a distant 
metastasis or a recurrent cancer. SEER standardized the coding of multiple primary cancers 
diagnosed in an individual cancer patient, including cancers that were diagnosed concurrent 
with or subsequent to the first primary cancer [12]. These rules have been revised over time 
[13–17] and are used throughout the United States and in the majority of Canadian 
provinces beginning in 2007 [18]. In addition, the International Association of Cancer 
Registries (IACR) has developed multiple primary coding rules that are used worldwide 
[19]. In general, SEER rules are more liberal than IACR rules in allowing the registration of 
multiple primary cancers, particularly cancers that occur in paired organs, at the same 
anatomic site and with the same histologic type.
To address issues of comparability, IACR has developed a computer software program that 
processes data about multiple primary cancers reported for the same cancer patient and 
produces a file consistent with IACR multiple primary rules [20]. This program has been 
used to process data from North American cancer registries for inclusion in Cancer 
Incidence in Five Continents [7] and by the CONCORD Programme, when reporting global 
cancer survival data [9].
Historically, usage of different multiple primary rules has not hindered comparative analyses 
of population-based cancer survival because estimates have been based on the first primary 
cancer (i.e., only primary cancer or first of two or more primary cancers) diagnosed in a 
patient [8–10, 21]. But recently, Brenner and Hakulinen [22] have cautioned against the 
exclusion of patients with a prior cancer for comparative analyses of population-based 
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cancer survival. As the authors noted, the proportion of cancer patients with a known prior 
cancer may depend on the length of operation of the cancer registry: Cancer registries that 
have been in operation for many years will have more information (i.e., past cancer 
diagnoses) with which to correctly identify a prior cancer than a cancer registry that has 
been in operation for fewer years. Because the prognosis of a subsequent cancer often differs 
from that of a first cancer (i.e., the inclusion of all cancers tends to produce somewhat lower 
survival estimates than those based solely on first cancers) [23, 24], the exclusion of cancer 
patients with a known prior cancer may introduce a bias in comparative studies because 
some cancers will be erroneously designated as first cancers when, in fact, they are 
subsequent cancers. The potential effect of this bias—if estimates are restricted to first 
cancers-only—will increase as the number and proportion of multiple primary cancers 
increases because of improved survival for many leading cancers [3, 8, 21, 25]. 
Furthermore, the mobility and migration patterns of North American populations are 
variable [26, 27], and a cancer registry may not have knowledge of a previous cancer if that 
cancer was diagnosed in a different state, province, or country.
International comparisons of cancer incidence [7] and survival [8, 9] are possible, but 
differences in the coding rules for multiple primary cancers need to be considered when 
comparing data. Although several studies have compared survival estimates by using first 
versus multiple cancers using IACR multiple primary rules [22–24], this study is the first, to 
our knowledge, to compare survival estimates by using both IACR and SEER multiple 
primary cancer rules among the same patient population.
Materials and methods
Source of data
Data collected according to SEER multiple primary cancer rules were available from cancer 
registries in five states (Connecticut, Hawaii, Iowa, New Mexico, Utah) and six 
metropolitan areas (Atlanta, Detroit, San Francisco-Oakland, Seattle, Los Angeles, San Jose
—Monterey) participating in the SEER Program [11] and covering approximately 14 % of 
the US population (SEER-11). Primary site and histology were coded according to the 
edition of the International Classification of Diseases for Oncology in use at the time of 
diagnosis, converted to the third edition [28], and categorized according to the SEER cancer 
site recodes [29]. Record-level data for patients diagnosed beginning 1 January 1973 (1974 
for Seattle, 1975 for Atlanta, and 1992 for Los Angeles and San Jose—Monterey) through 
31 December 2008 were extracted from the November 2010 data submission to the SEER 
Program by using the Case Listing Session feature in SEER*Stat software (Version 7.0.4, 
Information Management Services, Inc., Silver Spring, MD) and processed by using SAS 
(Version 9.2, Cary, NC). The IACR multiple primary program [20] was applied to the 
extracted data for the purpose of designating cases consistent with IACR multiple primary 
rules. The data were then processed by using SEER*Prep (Version 2.4.2, Information 
Management Services, Inc., Silver Spring, MD) for analysis in SEER*Stat.
The following cases were excluded: (a) in situ cancer (with the exception of in situ urinary 
bladder, which is considered invasive for incidence reporting) (n = 397,637) and (b) 
unknown age (n = 724). After these exclusions, 2,353,889 cases were diagnosed among 
Weir et al. Page 3













cancer patients aged 15 years or older from 1 January 1995 to 31 December 2008. More 
cases were excluded from the survival analysis because they did not contribute survival 
time: (a) vital status of alive with zero survival times (n = 20,416) and (b) cases reported 
solely on the basis of a death certificate or autopsy report (n = 29,537).
Analysis
Observed survival is the proportion of patients alive at some specified time after diagnosis 
following the identification of deaths from any and all causes, including cancer, and 
adjustment for the number of patients at risk of dying. Relative survival is the ratio of the 
observed to expected survival [30] where expected survival, for this analysis, was derived 
from life tables available in SEER*Stat titled “US 1970–2006 by individual year (White, 
Black, Other (AI/API) All races for Other Unspec 1991+ and Unknown).”
Relative survival estimates were calculated using SEER*Stat software (Version 8.0.2, 
Information Management Services, Inc., Silver Spring, MD) for all races combined by using 
the actuarial method on monthly follow-up, and the cumulative summary survival rates at 12 
months (1 year), 36 months (3 years), 60 months (5 years), and 120 months (10 years) are 
presented. All cancers and cancer-specific survival estimates were age-standardized to the 
International Cancer Survival Standards (ICSS) [31] by using five age-groups (15–44, 45–
54, 55–64, 65–74, and 75+). Confidence intervals for the estimates were calculated on the 
basis of a log (−[log]) transformation.
In this analysis, we looked at the total number of first primary cancers according to SEER 
multiple primary rules and the additional number (if any) of primary cancers according to 
SEER and IACR rules, respectively. Case counts and survival estimates were generated 
according to SEER primary site recodes [29]. Parallel analyses were conducted on three data 
sets (first primary cancers-only [First]; first and IACR multiple primary cancers [IACR 
MP]; first and SEER multiple primary cancers [SEER MP]) in order to compare all cancer 
sites combined and site-specific case counts and survival rates by using different multiple 
primary cancer coding rules. The percentage of multiple primary cancer cases was 
calculated for both the SEER and IACR data sets, and sites with the largest absolute 
differences were ranked. For the SEER MP and IACR MP survival analyses, only the first 
primary cancer that matched to the selection criteria was used, such that an individual could 
contribute no more than one case per site category. For example, if a person had two oral 
cavity cancers and one esophagus cancer, they would contribute the earlier of the two oral 
cavity cases to the survival statistics for the oral cavity site category, the esophagus case to 
the esophagus category, and only the earliest of the three tumors to the “All sites” grouping.
There is no formal statistical test to compare survival estimates on (nearly) the same 
population by using different analytic methods. Therefore, we noted differences where 5-
year point estimates from the first data set were not contained within the corresponding 95 
% CIs from the SEER and IACR data sets, respectively. Differences were noted where 5-
year point estimates from the IACR MP data set were not contained within the 
corresponding 95 % CIs from the SEER MP data set.
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Figure 1 shows the percentage of multiple primary cancers (all sites and both sexes 
combined) by year of diagnosis according to SEER and IACR multiple primary cancer 
coding rules. In 1995, 14.6 and 13.2 %, respectively, of all cancers were reported as multiple 
primary according to SEER and IACR rules. Between 2005 and 2006, the percentage of 
multiple primaries declined slightly before continuing to increase. By 2008, the percentage 
of multiple primary cancers increased to 18.4 % (+25.4 %) according to SEER rules and to 
15.8 % (+20.1 %) according to IACR rules.
Table 1 shows the number of first primary cancer sites, by sex, according to SEER multiple 
primary cancer rules; the number and percentage of additional cancers by using IACR and 
SEER rules; and the percentage difference between SEER and IACR rules, for all cancer 
sites combined and the top 25 cancer sites for cancer patients aged 15 years or older at 
diagnosis and diagnosed between 1995 and 2008 in the SEER-11 area. During 1995–2008, 
there were 1,015,564 males and 951,022 females diagnosed with at least one primary cancer. 
According to SEER rules, 189,933 (15.8 %) and 197,370 (17.2 %) additional primary 
cancers were diagnosed among males and females, respectively. According to IACR rules, 
171,363 (14.4 %) and 160,946 (14.5 %) additional primary cancers were diagnosed among 
males and females, respectively. For each of the top 25 cancer sites and all cancer sites 
combined, SEER rules identified more multiple primaries than IACR rules. The largest 
differences in the number of multiple primary cancers between the two rule sets, in rank 
order, were as follows: melanoma of the skin (5.8 %), urinary bladder (3.5 %), kidney and 
renal pelvis (2.9 %), colon and rectum (2.7 %), and oral cavity and pharynx (1.6 %) among 
males; and breast (5.9 %), melanoma of the skin (3.9 %), urinary bladder (3.4 %), colon and 
rectum (2.9 %), and oral cavity and pharynx (2.2 %) among females.
Table 2 shows 1-, 3-, 5-, and 10-year age-standardized relative survival (RS%) estimates and 
95 % CI for all cancer sites combined and for the top 25 cancer sites among males and 
females for each data set (First, SEER MP, and IACR MP) and differences for First versus 
SEER MP and IACR MP, respectively, and between SEER MP and IACR MP data sets. 
Differences where the point estimate from one data set was not contained within the 
confidence interval for the comparative data set were noted. Compared with estimates using 
first primary cancers-only, those that included all first primary cancers matching the 
selection criteria gave more conservative (i.e., lower) 5-year survival estimates for all sites 
combined (SEER: RS −1.30 %, IACR: RS −1.29 %) among males and (SEER: RS −0.23 %, 
IACR: RS −0.55 %) among females, respectively; and for 11 of the top cancers: oral cavity 
and pharynx (RS −2.26 %, RS −2.20 %), colon and rectum (RS −1.31 %, RS −1.30 %), 
larynx (RS −1.62 %, RS - 1.59 %), melanoma of the skin (RS −1.05 %, RS −1.12 %), 
prostate (RS −1.06 %, RS −1.07 %), urinary bladder (RS −2.37 %, RS −2.06 %), kidney and 
renal pelvis (RS −0.78 % SEER only), thyroid (RS −1.90 %, RS −1.92 %), Hodgkin’s 
lymphoma (RS −1.28 %, RS - 1.22 %), non-Hodgkin’s lymphoma (RS −0.76 %, RS −0.68 
%), and leukemia (RS −0.91 %, RS −0.86 %) among males and oral cavity and pharynx (RS 
−1.73 %, RS −1.74 %), colon and rectum (RS −0.69 %, RS −0.69 %), larynx (RS −2.72 %, 
RS −2.72 %), melanoma of the skin (RS −0.89 %, RS −0.88 %), breast (RS −0.76 %, RS 
−0.67 %), corpus and uterus, NOS (RS −1.40 %, RS −1.40 %), urinary bladder (RS −2.54 
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%, RS −2.28 %), kidney and renal pelvis (RS −0.89 % SEER only), thyroid (RS −0.78 %, 
RS −0.77 %), non-Hodgkin’s lymphoma (RS −0.77 %, RS −0.68 %), and leukemia (RS 
−1.99 %, RS −1.95 %) among females. Five-year cancer survival estimates differed between 
SEER MP and IACR MP for all sites combined (RS 0.32 %) among females.
Discussion
This study provided a unique opportunity to evaluate the effect of two widely used multiple 
primary cancer coding rules, SEER and IACR, on population-based survival estimates using 
SEER-11 cancer survival data, covering approximately 14 % of the US population.
Until recently, the presence of multiple primary cancers and the rules used to collect and 
report these cases were generally not considered in survival analyses because population-
based survival estimates were based on first primary cancers—either the only cancer 
diagnosed in a patient or the first of multiple primary cancers diagnosed [8, 9, 21]. However, 
this practice is no longer advocated because it can result in the exclusion of a relatively large 
and growing number of cancer patients and can lead to the introduction of biases into 
survival analyses [22].
In the United States, the percentage of multiple primary cancers by using SEER rules is 
relatively large and increasing. The percentage was higher in females compared to males 
(17.2 vs. 15.8 %) reflecting, in large part, the influence of these rules on female breast 
cancer counts. Between 1995 and 2008, the percentage of multiple primary cancers 
increased 25.4 % among SEER-11 registries. This increase reflects improved survival for 
many adult cancers and the fact that cancer patients remain at risk, and in some cases 
increased risk, of developing subsequent primary cancers [32]. The SEER rules have 
changed over time and field studies to test the most recent rules began in late 2005 and may 
account for the slight reduction in the percentage of multiple primary cancers observed 
between 2005 and 2006. The rules were modified to include longer time requirements 
between same site primaries for certain sites [17].
This study confirmed the finding from previous studies [23, 24] that survival estimates 
based on first cancers-only exclude a large, varied, and increasing number of subsequent 
primary cancers and generally produce less conservative (i.e., higher) 5-year survival 
estimates than estimates produced by using all primary cancers based on SEER or IACR 
multiple primary cancer coding rules. Therefore, attempting to exclude subsequent cancers 
could introduce a systematic bias into survival analyses if the rules for registering multiple 
primaries are not applied consistently among all registries, or over time within a registry, or 
if information on previous cancer diagnoses is missing.
Clinicians may intuitively recognize a new primary cancer from that of a distant metastasis, 
extension, or recurrent cancer. However, it can be difficult to codify the rules for reporting 
these cancers by using routinely collected surveillance data. The identification of multiple 
primary cancers may reflect the following: (1) the quality and completeness of the 
surveillance data being reported to the cancer registry by hospitals, physicians’ offices, and 
laboratories and (2) the training of hospital and registry staff to code the data and interpret 
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the rules. These coding rules may be particularly challenging for registries that use SEER 
rules because these rules are more complex and require more detailed information than 
IACR rules. Cancer registries may lack information on previous cancers if the patient was 
diagnosed in a different state, province, or country from their current residence. This lack of 
information could be problematic for cancer registries in the United States because registries 
operate independently in each of the 50 states, the District of Columbia, and six 
metropolitan areas [6] with support from one or both of the two federal cancer surveillance 
programs: the National Cancer Institute’s SEER Program [11] or the Centers for Disease 
Control and Prevention’s National Program of Cancer Registries (NPCR) [4]. NPCR-funded 
cancer registries could be particularly impacted because many of them have been fully 
operational since the mid-1990s or later, and SEER metropolitan area registries, with 
substate catchment areas.
Furthermore, survival estimates based on first cancers-only do not represent the clinical 
experience of the entire cancer patient population [23]. For example, the introduction of 
screening practices, such as the prostate-specific antigen (PSA) test, may advance the 
diagnosis date of prostate cancer by many years before the cancer would be, if at all, 
clinically detectable. Early-stage prostate cancers can have high survival rates [32], and a 
patient may die from a subsequent cancer (e.g., colorectal) rather than their prostate cancer. 
Including both prostate and colorectal primary cancers in survival analyses would be 
clinically and epidemiologically relevant.
Although it clearly makes sense to use all primary cancers in population-based survival 
studies, the question remains: Does the choice of SEER or IACR multiple primary cancer 
coding rules affect survival estimates? This study did not find any appreciable difference 
between site-specific survival estimates based on SEER or IACR multiple primary rules. 
SEER multiple primary coding rules are more liberal than IACR rules in allowing the 
registration of multiple primary cancers, particularly cancers that occur at the same site 
including paired organs (breast, kidney) and organs with relatively large surface areas (skin, 
urinary bladder, colon and rectum, oral cavity and pharynx). However, for both the SEER 
MP and the IACR MP analyses, cases were selected based on using the first cancer that 
matched to the selection criteria (first cancer in primary site category). This selection 
criterion appears to have mitigated the influence of SEER multiple primary rules. The one 
exception was for all sites combined among females where SEER rules produced marginally 
higher survival estimates than IACR rules (RS 62.28 vs. 61.96 %, respectively). In preparing 
the data sets, the IACR rules were applied to data from all diagnosis years, including those 
prior to the reference years for this study (1995–2008) that resulted in the exclusion of some 
cases that the SEER rules identified as multiple primary cancers. Hence, the case counts 
differed for the all sites combined category (Table 1) as did the survival estimates (Table 2).
In conclusion, our results showed that survival estimates based on SEER multiple primary 
rules, which are used by cancer registries in the United States and in the majority of 
provincial registries in Canada [18], are comparable to those based on IACR rules, which 
are used by cancer registries throughout the remaining world, when site-specific analyses 
include all first primary cancers matching the selection criteria. Therefore, to produce 
clinically and epidemiologically relevant and less biased cancer survival estimates, 
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researchers may consider including data on all cancers in their analysis. However, the 
multiple primary rules used to collect and record the cancer case data do not affect survival 
estimates if all first cancers matching the selection criteria are used to produce site-specific 
survival estimates.
Population-based cancer survival is an important outcome measure for assessing cancer 
control and health policy initiatives. Together with information on cancer incidence and 
death, survival data can be used to evaluate progress in preventing, screening, diagnosing, 
and treating cancer patients [33]. To facilitate the comparison and interpretation of 
international data and to align the incidence data more closely with the cases used in the 
survival analyses, cancer registries in North America may want to consider publishing 
population-based incidence and survival statistics that are based on IACR multiple primary 
cancer coding rules.
Limitation
Survival estimates from this study were calculated for the purpose of comparing SEER and 
IACR multiple primary cancer coding rules and were not intended to represent the survival 
experience of cancer patients in the study area. Life expectancy varied among geographic 
areas in the United States [9, 34], and estimates were not adjusted for state-specific life 
expectancy because these life tables are not currently available. Life tables were based on 
the life expectancy of the general population. As such, these tables may overestimate life 
expectancy for individuals with subsequent cancers.
Abbreviations
ICD International Classification of Diseases
IACR International Association of Cancer Registries
NAACCR North American Association of Central Cancer Registries
NPCR National Program of Cancer Registries
SEER Surveillance, Epidemiology, and End Results
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